Moderna, Inc. Revenue & Financials

Moderna reported Total Revenue of $1.944 billion for fiscal year 2025, a 40% decrease from the $3.236 billion recorded in 2024, reflecting the continued collapse of COVID-19 vaccine demand from pandemic peaks. Net product sales were $1.818 billion, down from $3.109 billion in 2024, with U.S. sales of $1.2 billion and international sales of $745 million. The company reported a GAAP net loss of $2.822 billion, or $7.26 per share, compared to a net loss of $3.561 billion, or $9.28 per share, in 2024, representing a 21% improvement in net loss despite the revenue decline. This improvement was driven by cost reductions: cost of sales declined 41% to $868 million, R&D expenses declined 31% to $3.1 billion, and SG&A expenses declined 13% to $1.0 billion. Total operating expenses were $5.018 billion in 2025, down from $7.181 billion in 2024, reflecting the company's aggressive cost-cutting program. The gross margin on product sales remained negative when including inventory write-downs of $291 million and unutilized manufacturing capacity costs. Interest income contributed $314 million, partially offsetting operating losses. The company ended 2025 with cash, cash equivalents, and investments of approximately $6 billion, down from $9.5 billion at year-end 2024, representing a cash burn rate of approximately $3.5 billion for the year. The 2026 revenue guidance projects up to 10% growth, to approximately $2.1 billion, with a 50-50 U.S.-international sales mix compared to 62% U.S. in 2025. The company expects to reduce operating expenses further in 2026, with a target of $1.5 billion in total cost savings by 2027 compared to 2024 levels. Capital expenditures in 2025 were approximately $0.3 billion, down from previous expectations of $0.4 billion, as the company deferred non-essential infrastructure projects. The financial architecture is characterized by high fixed costs, seasonal revenue concentration, and a transition from profitable pandemic contracting to loss-making endemic commercialization. The path to cash break-even by 2028 depends on achieving $3-4 billion in annual revenue, which would require successful launches of the flu vaccine, norovirus vaccine, and oncology products, combined with continued cost discipline. The company's market capitalization of approximately $18.8 billion as of June 2026 reflects investor skepticism about the near-term revenue trajectory, with the stock trading at a price-to-sales ratio of approximately 8.4x, below the biotechnology sector average. The balance sheet provides roughly two years of runway at current burn rates, creating urgency around pipeline execution and potential capital raising if milestones are delayed. The company's capital structure, which includes no significant long-term debt, provides flexibility but also limits access to debt markets for additional funding. The company's equity financing history, which includes multiple public offerings and the 2018 IPO, demonstrates access to capital markets but at increasingly dilutive terms. The company's share repurchase program, which has consumed $3 billion in cash since 2022, has been criticized as a poor use of capital given the company's funding needs and declining share price. The company's institutional shareholder base, which includes Vanguard, BlackRock, and State Street, has remained relatively stable, providing some support for the stock price, but these investors may reduce positions if the company's financial performance does not improve. The company's analyst coverage, which includes more than 20 investment banks, provides visibility but also creates pressure to meet quarterly expectations. The company's credit rating, while not formally rated by major agencies, would likely be speculative grade given the company's net losses and declining cash position. The company's ability to access capital markets, whether through equity offerings, debt financing, or strategic partnerships, will be critical for funding the pipeline and achieving cash break-even. The financial narrative is therefore one of a company that has experienced extraordinary financial volatility, from pandemic profitability to endemic losses, and must now navigate a funding environment that is increasingly skeptical of biotechnology companies with unproven commercial models.